Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Which diabetes pill combo works best? new study pits three options Head-to-Head

NCT ID NCT06759922

First seen Nov 21, 2025 · Last updated Jun 22, 2026 · Updated 35 times

Summary

This completed study tested different combinations of diabetes drugs (glimepiride, empagliflozin, or sitagliptin) taken with metformin in 172 adults newly diagnosed with type 2 diabetes. Participants were split into four groups and took their assigned pills once daily for 90 days. Researchers measured blood sugar control (HbA1c), weight, cholesterol, and side effects to see which combination worked best and was safest.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • National Medical Center

    Karachi, Sindh, 75500, Pakistan

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Metformin combined with glimepiride, empagliflozin, or sitagliptin

What this could lead to

If successful, this could help doctors choose the most effective and safe two- or three-drug combination for managing blood sugar in newly diagnosed type 2 diabetes patients.

What could go wrong

This is a small, completed Phase 4 trial, so results may not apply to all patients. Side effects like diarrhea, weight gain, or urinary infections are possible with these drugs.

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.